Core Insights - As of December 24, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.959 billion yuan, an increase of 71.38 million yuan from the previous trading day, marking a continuous increase for four consecutive trading days [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest balances of 399 million yuan, 370 million yuan, and 339 million yuan respectively [1] - A total of 182 stocks on the Beijing Stock Exchange received net margin purchases on December 24, with 44 stocks having net purchases exceeding 1 million yuan, led by Tianli Composite with a net purchase of 9.5846 million yuan [1][2] Margin Financing Overview - The margin financing balance increased for the following stocks on December 24: - Tianli Composite: 572.73 million yuan, up by 9.5846 million yuan, with a market value ratio of 0.67% [2] - Tiangong Co.: 321.16 million yuan, up by 6.5918 million yuan, with a market value ratio of 2.46% [2] - Hongyu Packaging: 254.18 million yuan, up by 6.407 million yuan, with a market value ratio of 0.83% [2] Industry Performance - The industries with the highest concentration of stocks receiving net margin purchases over 1 million yuan include machinery equipment, automotive, and basic chemicals, with 6, 5, and 4 stocks respectively [2] - On December 24, stocks with net margin purchases exceeding 1 million yuan had an average increase of 0.98%, with notable gainers including Tiangong Co. (up 16.15%), Jiahe Technology (up 9.60%), and Litong Technology (up 6.73%) [2] - The average turnover rate for stocks with net margin purchases over 1 million yuan was 4.60%, with the highest turnover rates seen in Tiangong Co. (38.53%), Xingchen Technology (21.24%), and Knight Dairy (18.00%) [2]

Group 1 - Huayuan Co., Ltd. reported progress in the construction of its intelligent manufacturing base in Hubei and disclosed operational data for the first half of 2025 [1] - Lingge Technology announced new developments in its solid-state battery business, with a year-on-year increase in orders on hand [2] - Jiaxian Co., Ltd. shared updates on its photoresist business and a dual-wheel adjustment strategy during an investor meeting [3] Group 2 - Jinbo Bio announced plans to increase the registered capital of its wholly-owned subsidiary by RMB 165 million to support business development [4] - Qianjin Technology is utilizing RMB 15 million of its idle funds to purchase bank wealth management products to enhance fund efficiency [5] - Yiguangming is using RMB 30 million of its idle funds and RMB 18 million of raised funds for wealth management to improve fund efficiency [6] - Zecheng Electronics is investing RMB 26.9373 million of its idle funds in wealth management products [7] - Lijia Technology is allocating RMB 83 million of its idle funds for wealth management to enhance fund efficiency [8] Group 3 - Audiwei received a project designation notice from a leading intelligent driving system integrator, with an expected contract value of RMB 176 million [9] - Sanwei Equipment announced that several shareholders plan to reduce their holdings, with a maximum reduction of 1% of shares [10] - Guohang Ocean's wholly-owned subsidiary obtained a patent for a method and system for identifying abnormal behavior in ship entry and exit speeds, enhancing the company's competitive edge [11]

Core Viewpoint - Jinbo Bio announced the approval of two significant proposals during its board meeting, indicating a strategic move towards enhancing its financial capabilities and supporting its subsidiary's growth [2] Group 1: Financial Strategies - The company plans to apply for a new type of policy-based financial instrument from the China Export-Import Bank, which may provide additional funding and support for its operations [2] - A proposal to increase the registered capital of its wholly-owned subsidiary was also approved, suggesting a focus on strengthening its subsidiary's financial position and operational capacity [2]

证券代码：920982 证券简称：锦波生物 公告编号：2025-185 山西锦波生物医药股份有限公司 关于拟向全资子公司增加注册资本的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、对外投资概述 （一）基本情况 根据公司战略发展规划及业务发展需要，公司拟向全资子公司锦波医学生 物材料（北京）有限公司（以下简称"锦波医学"）增资人民币 16,500 万元， 本次增资完成后锦波医学的注册资本由人民币 3,500 万元增加至人民币 20,000 万元。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 根据《上市公司重大资产重组管理办法》的相关规定，本次对外投资系对 全资子公司增资，不构成重大资产重组。 （七）投资对象是否开展或拟开展私募投资活动 本次交易标的不涉及开展或拟开展私募投资活动，不是已在中国证券投资基 金业协会登记为私募基金管理人，不会将公司主营业务变更为私募基金管理业务。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）决策与审议程序 公司于 2025 年 12 月 2 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：920982 证券简称：锦波生物 公告编号：2025-184 （一）会议召开情况 1.会议召开时间：2025 年 12 月 23 日 山西锦波生物医药股份有限公司 第四届董事会第十八次会议决议公告 4.发出董事会会议通知的时间和方式：2025 年 12 月 20 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）审议通过《关于拟向全资子公司增加注 ...

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.49% on December 24, with Huaxi Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3940.95, up by 0.53% [1] - The Shenzhen Component Index closed at 13486.42, up by 0.88% [1] - The medical beauty sector's individual stock performance varied, with Huaxi Biological closing at 43.77, up by 0.67% [1] Group 2: Stock Performance and Trading Volume - Huaxi Biological (688363) had a trading volume of 23,600 shares and a transaction value of 103 million yuan [1] - *ST Meigu (000615) closed at 4.20, with a trading volume of 113,300 shares and a transaction value of 47.07 million yuan [1] - Aimeike (300896) closed at 142.80, with a trading volume of 14,900 shares and a transaction value of 213 million yuan [1] - Jinbo Biological (920982) closed at 247.48, with a trading volume of 6,149 shares and a transaction value of 152 million yuan [1] Group 3: Capital Flow Analysis - The medical beauty sector saw a net inflow of 8.54 million yuan from main funds, while retail funds experienced a net inflow of 987,200 yuan [1] - Main funds showed a net inflow of 8.24 million yuan for Huaxi Biological, while retail funds had a net inflow of 478,000 yuan [2] - Aimeike had a net inflow of 3.80 million yuan from main funds, but a net outflow of 3.31 million yuan from retail funds [2]

Core Viewpoint - The medical beauty sector experienced a decline of 1.37% on December 23, with Ai Meike leading the drop, while the overall market indices showed slight increases [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3919.98, up 0.07% [1] - The Shenzhen Component Index closed at 13368.99, up 0.27% [1] - The medical beauty sector saw a net outflow of 64.78 million yuan from main funds, while retail investors contributed a net inflow of 39.45 million yuan [1] Group 2: Individual Stock Performance - Jinbo Biological (code: 920982) closed at 249.76, with a gain of 1.33% and a trading volume of 88,613.2 hands, totaling 218 million yuan [1] - ST Meigu (code: 000615) closed at 4.18, down 0.95% with a trading volume of 215,700 hands, totaling 9.28 million yuan [1] - Huaxi Biological (code: 688363) closed at 43.48, down 1.29% with a trading volume of 24,700 hands, totaling 108 million yuan [1] - Ai Meike (code: 300896) closed at 142.29, down 1.46% with a trading volume of 28,000 hands, totaling 400 million yuan [1] Group 3: Fund Flow Analysis - Jinbo Biological saw a main fund net inflow of 6.66 million yuan, with a main fund net ratio of 3.05% [2] - ST Meigu experienced a main fund net outflow of 1.76 million yuan, with a net inflow from retail investors of 2.50 million yuan [2] - Huaxi Biological had a main fund net outflow of 14.61 million yuan, with a retail net inflow of 6.11 million yuan [2] - Ai Meike faced a significant main fund net outflow of 48.42 million yuan, while retail investors contributed a net inflow of 30.84 million yuan [2]

Investment Rating - The report indicates a positive investment outlook for the industry, suggesting a focus on structural investment opportunities driven by policy expectations [2][28]. Core Insights - The North Exchange market showed an average daily trading volume of 22.62 billion yuan, a 16.0% increase week-on-week, while the North Certificate 50 index fell by 0.13% [1][7]. - Key stocks that performed well included Tianli Composite (up 41.4%), Hanxin Technology (up 40.6%), and Hongxi Technology (up 26.0%), while the biggest losers were *ST Guandao (down 41.5%) and Kangla Weishi (down 20.0%) [1][14]. - The macroeconomic environment is characterized by a dual drive of strengthened policy expectations and boosted domestic demand, with a focus on consumer service-related enterprises benefiting from favorable policies [2][28]. Summary by Sections Market Overview - The North Exchange's average daily trading volume reached 22.62 billion yuan, reflecting a 16.0% week-on-week increase, with a daily turnover rate of 2.4% [1][7]. - The North Certificate 50 index experienced a slight decline of 0.13% during the week [1][7]. Key News and Policies - Xi Jinping emphasized the strategic importance of expanding domestic demand to maintain economic stability, advocating for measures to stimulate consumption and optimize income distribution [17][20]. - The Ministry of Industry and Information Technology announced the first batch of L3 conditional autonomous driving vehicle approvals, enhancing interest in the smart driving industry chain [19][29]. Core Driving Factors - The report highlights a positive market sentiment with increased trading activity, as evidenced by the 16.0% rise in average daily trading volume [28][31]. - The focus on emerging industries such as commercial aerospace, autonomous driving, and new energy is expected to drive growth [28][30]. Investment Recommendations and Strategies - The report suggests focusing on new productive forces, particularly in emerging sectors like commercial aerospace, autonomous driving, and biotechnology, while also considering companies with high growth potential based on financial metrics [32]. - Short-term attention is recommended for North Certificate 50 weighted stocks and newly added index constituents, which may benefit from passive allocation demands from index funds [32].

Group 1 - The medical beauty sector experienced a decline of 0.49% on December 22, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3917.36, up by 0.69%, while the Shenzhen Component Index closed at 13332.73, up by 1.47% [1] - A detailed table of individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector saw a net outflow of 63.79 million yuan from main funds, while retail funds had a net inflow of 15.31 million yuan [2] - The net inflow from speculative funds was 48.47 million yuan [2] - A detailed table of capital flow for individual stocks in the medical beauty sector is included [2]

Group 1 - The report highlights the performance of the North Exchange in 2025, indicating a significant rise in the North Index 50 to around 1400 points, with three distinct phases of market movement: rapid increase, oscillating rise, and a correction phase [2][12][15] - In the rapid increase phase (January 1 - March 11, 2025), the North Index 50 surged from 1,037.81 to 1,418.65 points, achieving a cumulative return of 36.70%, while the specialized index rose from 1,683.33 to 2,421.50 points, with a return of 43.85% [15][16] - The oscillating rise phase (April 7 - September 5, 2025) saw the North Index 50 increase from 1,044.07 to 1,647.01 points, yielding a cumulative return of 58.70%, and the specialized index from 1,759.64 to 2,806.39 points, with a return of 66.72% [16][17] Group 2 - The correction phase (September 15 - December 19, 2025) stabilized the North Index 50 and specialized index around 1400 and 2400 points, respectively, with the North Index 50 declining to 1,445.84 points and the specialized index to 2,440.21 points, resulting in cumulative returns of 39.32% and 44.96% [17][23] - The report emphasizes the performance of small-cap stocks, indicating that companies with market capitalizations of 0-20 billion, 20-40 billion, 40-80 billion, and above 80 billion had average returns of 54.08%, 38.60%, 18.26%, and 30.59%, respectively [26][31] - The report identifies that national and provincial-level "little giant" companies outperformed non-little giant firms, with average returns of 48.26%, 38.06%, and 39.19% for national, provincial, and non-little giants, respectively [27][29] Group 3 - The report highlights that national and provincial-level single champion companies achieved average returns of 59.27% compared to 39.61% for non-single champion companies [32][34] - In terms of industry performance, high-end equipment and new chemical materials sectors showed higher returns, with average returns of 50.20%, 28.67%, 48.49%, 40.43%, and 43.56% for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, respectively [34][36] - The report also notes that companies with new productive forces, ESG attributes, high scarcity, and high dividends had average returns of 50.49%, 48.44%, 49.14%, and 57.51%, respectively, indicating a strong performance in these categories [37][43]